Whereas activation of the CREBH–Fgf21 axis protects mice from HFD-induced obesity, IR, and hepatic steatosis (6, 7), the current study was designed to explore whether its activation would reverse these disorders once established. The gene discussed is CREB3L3; the disease is obesity due to melanocortin 4 receptor deficiency.